Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 2/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
| ▸ | GSK3A | P49840 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | MET | P08581 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 3/20 | 0.31 |
| ▸ | JAK1 | P23458 | 3/20 | 0.31 |
| ▸ | TYK2 | P29597 | 3/20 | 0.31 |
| ▸ | JAK3 | P52333 | 3/20 | 0.31 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL660078 | 0.87 | USP30 (0.49) | FFAR1USP30DGAT1DDB1CRBN | |
| SCHEMBL2363986 | 0.86 | FFAR1 (0.44) | FFAR1USP30DGAT1IRAK4GSK3A | |
| SCHEMBL22032011 | 0.86 | FFAR1 (0.44) | FFAR1USP30DGAT1CHRNB2CHRNA4 | |
| SCHEMBL22086365 | 0.84 | FFAR1 (0.42) | FFAR1USP30CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL25429659 | 0.83 | NR1H2 (0.46) | FFAR1DGAT1 | |
| SCHEMBL23211127 | 0.80 | FFAR1 (0.41) | FFAR1USP30JAK1TYK2JAK3 | |
| SCHEMBL31260505 | 0.80 | FFAR1 (0.41) | FFAR1USP30DGAT1ROCK2GSK3B | |
| SCHEMBL23211118 | 0.80 | FFAR1 (0.41) | FFAR1USP30JAK1TYK2JAK3 | |
| SCHEMBL16342703 | 0.80 | FFAR1 (0.41) | FFAR1USP30JAK1TYK2JAK3 | |
| SCHEMBL25236223 | 0.80 | USP30 (0.45) | FFAR1USP30DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11040981-B2 | Pyrrolotriazine compounds and methods of inhibiting TAM kinases | SYROS PHARMACEUTICALS, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| US-11040981-B2 | Pyrrolotriazine compounds and methods of inhibiting TAM kinases | SYROS PHARMACEUTICALS, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| US-20210147431-A1 | PYRROLOTRIAZINE COMPOUNDS AND METHODS OF INHIBITING TAM KINASES | SYROS PHARMACEUTICALS INC (US) | 2021-05-20 | — | — | US | disclosed |
| US-20210147431-A1 | PYRROLOTRIAZINE COMPOUNDS AND METHODS OF INHIBITING TAM KINASES | SYROS PHARMACEUTICALS INC (US) | 2021-05-20 | — | — | US | disclosed |
| CN-112368285-A | Pyrrolotriazine compounds and methods of inhibiting TAM kinase | 希洛斯医药品股份有限公司 | 2021-02-12 | — | — | CN | disclosed |
| US-20200317676-A1 | PYRROLOTRIAZINE COMPOUNDS AND METHODS OF INHIBITING TAM KINASES | SYROS PHARMACEUTICALS, INC. (US) | 2020-10-08 | — | — | US | disclosed |
| US-20200317676-A1 | PYRROLOTRIAZINE COMPOUNDS AND METHODS OF INHIBITING TAM KINASES | SYROS PHARMACEUTICALS, INC. (US) | 2020-10-08 | — | — | US | disclosed |
| EP-3694860-A1 | PYRROLOTRIAZINE COMPOUNDS AND METHODS OF INHIBITING TAM KINASES | Syros Pharmaceuticals, Inc. (US) | 2020-08-19 | — | — | EP | disclosed |
| WO-2019074962-A1 | PYRROLOTRIAZINE COMPOUNDS AND METHODS OF INHIBITING TAM KINASES | SYROS PHARMACEUTICALS, INC. (US) | 2019-04-18 | — | — | WO | disclosed |
| WO-2019074962-A1 | PYRROLOTRIAZINE COMPOUNDS AND METHODS OF INHIBITING TAM KINASES | SYROS PHARMACEUTICALS, INC. (US) | 2019-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147431-A1 | PYRROLOTRIAZINE COMPOUNDS AND METHODS OF INHIBITING TAM KINASES | PLK2, MAP3K5, CAMKK2 | FFAR1 3175/4885USP30 1702/4885DGAT1 3429/4885 |
| US-20200317676-A1 | PYRROLOTRIAZINE COMPOUNDS AND METHODS OF INHIBITING TAM KINASES | PLK2, MAP3K5, CAMKK2 | FFAR1 3175/4885USP30 1702/4885DGAT1 3429/4885 |
| US-11040981-B2 | Pyrrolotriazine compounds and methods of inhibiting TAM kinases | PLK2, MAP3K5, CAMKK2 | FFAR1 3175/4885USP30 1702/4885DGAT1 3429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.